Cargando…
Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group
| Autores principales: | , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2003
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376942/ http://dx.doi.org/10.1038/sj.bjc.6601177 |
| _version_ | 1782154756402184192 |
|---|---|
| author | Kollmannsberger, C Bokemeyer, C |
| author_facet | Kollmannsberger, C Bokemeyer, C |
| author_sort | Kollmannsberger, C |
| collection | PubMed |
| description | |
| format | Text |
| id | pubmed-2376942 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2003 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-23769422009-09-10 Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group Kollmannsberger, C Bokemeyer, C Br J Cancer Letter to the Editor Nature Publishing Group 2003-09-15 2003-09-09 /pmc/articles/PMC2376942/ http://dx.doi.org/10.1038/sj.bjc.6601177 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
| spellingShingle | Letter to the Editor Kollmannsberger, C Bokemeyer, C Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group |
| title | Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group |
| title_full | Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group |
| title_fullStr | Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group |
| title_full_unstemmed | Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group |
| title_short | Reply: Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group |
| title_sort | reply: irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase ii study of the german testicular cancer study group |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376942/ http://dx.doi.org/10.1038/sj.bjc.6601177 |
| work_keys_str_mv | AT kollmannsbergerc replyirinotecaninpatientswithrelapsedorcisplatinrefractorygermcellcanceraphaseiistudyofthegermantesticularcancerstudygroup AT bokemeyerc replyirinotecaninpatientswithrelapsedorcisplatinrefractorygermcellcanceraphaseiistudyofthegermantesticularcancerstudygroup |